#1 Clinical Trials Search in Europe

Duvakitug

Duvakitug, also known as TEV-48574, is an investigational drug being studied for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. These conditions are types of inflammatory bowel disease (IBD) that cause inflammation in the digestive tract. Clinical trials are currently underway to evaluate the effectiveness, safety, and long-term effects of Duvakitug in adult patients with these conditions. The studies aim to determine the optimal dosing and assess various measures of disease improvement.

Table of Contents

What is DUVAKITUG?

DUVAKITUG, also known as TEV-48574, is an investigational medication being developed for the treatment of inflammatory bowel disease (IBD)[1]. It is a new type of protein-based drug that is currently being studied in clinical trials to evaluate its effectiveness and safety in patients with moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD)[2].

What Conditions Does DUVAKITUG Treat?

DUVAKITUG is being investigated for the treatment of two main types of inflammatory bowel disease:

  • Ulcerative Colitis (UC): A chronic condition that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum[1].
  • Crohn’s Disease (CD): A chronic inflammatory condition that can affect any part of the digestive tract, from the mouth to the anus[1].

Both of these conditions are characterized by symptoms such as abdominal pain, diarrhea, rectal bleeding, and fatigue, which can significantly impact a person’s quality of life[1].

How Does DUVAKITUG Work?

While the exact mechanism of action of DUVAKITUG is not fully described in the provided clinical trial information, it is likely that as a protein-based drug, it targets specific inflammatory pathways involved in IBD[1]. Many newer IBD treatments work by modulating the immune system to reduce inflammation in the digestive tract.

How is DUVAKITUG Administered?

DUVAKITUG is administered as a subcutaneous injection. This means it is injected under the skin. The clinical trials describe using a B. Braun Perfusor® Space Syringe Pump to deliver the medication at a controlled rate of 30 mL/hour[1]. In the initial study, the drug is given every 2 weeks (Q2W), while in the long-term extension study, it is administered every 4 weeks (Q4W)[2].

Current Clinical Trials

DUVAKITUG is currently being studied in two main clinical trials:

  1. RELIEVE UCCD: A 14-week Phase 2b study to determine the pharmacokinetics, efficacy, safety, and tolerability of DUVAKITUG in adults with moderate to severe UC or CD[1].
  2. RELIEVE UCCD LTE: A long-term extension study to evaluate the long-term effects of DUVAKITUG in patients who completed the initial 14-week study[2].

Efficacy of DUVAKITUG

The clinical trials are designed to measure the efficacy of DUVAKITUG using several key endpoints:

  • For Ulcerative Colitis:
    • Clinical remission based on the modified Mayo score[2]
    • Endoscopic improvement and remission[1]
    • Clinical response based on patient-reported outcomes[1]
  • For Crohn’s Disease:
    • Endoscopic response based on the Simple Endoscopic Score for Crohn’s Disease (SES-CD)[2]
    • Clinical remission based on the Crohn’s Disease Activity Index (CDAI)[1]
    • Clinical response based on patient-reported outcomes[1]

The results of these trials will help determine how effective DUVAKITUG is in treating the symptoms and underlying inflammation of UC and CD.

Safety and Side Effects

As with any new medication, the safety of DUVAKITUG is being closely monitored in the clinical trials. The studies are designed to track:

  • Adverse events
  • Changes in laboratory test results
  • Changes in vital signs
  • Electrocardiogram (ECG) findings
  • Local tolerability at the injection site[1]

The trials also monitor for the development of anti-drug antibodies, which can affect the effectiveness and safety of protein-based drugs[1].

Future Research

The ongoing clinical trials will provide valuable information about the effectiveness and safety of DUVAKITUG in treating IBD. If the results are positive, future research may include larger Phase 3 trials and studies in different patient populations. The long-term extension study, which can last up to 5 years, will provide important data on the long-term effects and safety of DUVAKITUG[2].

It’s important to note that DUVAKITUG is still an investigational drug and is not yet approved for general use. Patients interested in this treatment should discuss current approved options with their healthcare provider and consider participation in clinical trials if appropriate.

Aspect Details
Drug Name Duvakitug (TEV-48574)
Conditions Studied Moderate to severe ulcerative colitis and Crohn’s disease
Administration Method Subcutaneous injection
Trial Phases Phase 2b (dose-ranging and long-term extension)
Primary Objectives Assess efficacy in inducing clinical remission (UC) and endoscopic response (CD)
Secondary Objectives Evaluate safety, tolerability, and immunogenicity
Key Endpoints Clinical remission, endoscopic improvement, corticosteroid-free remission
Trial Duration Initial 14 weeks, followed by up to 5 years in long-term extension
Patient Population Adults aged 18-75 with moderate to severe UC or CD
Safety Monitoring Adverse events, laboratory tests, vital signs, ECG, injection site reactions

FAQ

  • What is Duvakitug and what conditions is it being studied for? Duvakitug (TEV-48574) is an experimental drug being investigated for the treatment of moderate to severe ulcerative colitis and Crohn's disease, which are types of inflammatory bowel disease (IBD).
  • How is Duvakitug administered in the clinical trials? In the clinical trials, Duvakitug is administered as a subcutaneous injection (under the skin) using a syringe pump. The dosing schedule varies, with some patients receiving it every 2 weeks and others every 4 weeks.
  • What are the main goals of the Duvakitug clinical trials? The main goals are to evaluate the effectiveness of Duvakitug in inducing and maintaining clinical remission in ulcerative colitis and endoscopic response in Crohn's disease. The trials also assess safety, tolerability, and the body's immune response to the drug.
  • How long do the Duvakitug clinical trials last? The initial trial lasts 14 weeks, followed by a long-term extension study that can last up to 5 years. This allows researchers to evaluate both short-term and long-term effects of the drug.
  • What are some of the key measurements used in the Duvakitug trials? Key measurements include clinical remission based on symptom scores, endoscopic improvement (assessed through internal examinations), changes in disease activity indexes, and corticosteroid-free remission. The trials also monitor for side effects and the development of antibodies against the drug.

Ongoing Clinical Trials on Duvakitug

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Not yet recruiting

    3 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Not yet recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria Bulgaria Czechia Germany Hungary Italy +4

  • Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease

    Not recruiting

    2 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +6

Glossary

  • Inflammatory Bowel Disease (IBD): A group of disorders that cause chronic inflammation of the digestive tract. The two main types are ulcerative colitis and Crohn's disease.
  • Ulcerative Colitis: A type of IBD that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum.
  • Crohn's Disease: A type of IBD that can affect any part of the digestive tract from the mouth to the anus, causing inflammation that often spreads deep into affected tissues.
  • Clinical Remission: A state where the signs and symptoms of the disease are significantly reduced or absent, often measured by specific scoring systems.
  • Endoscopic Response: Improvement in the appearance of the intestinal lining as viewed through an endoscope, often measured by a reduction in visible inflammation or ulceration.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Mayo Score: A scoring system used to assess the severity of ulcerative colitis, considering factors like stool frequency, rectal bleeding, and endoscopic findings.
  • Simple Endoscopic Score for Crohn's Disease (SES-CD): A tool used to evaluate the severity of Crohn's disease based on endoscopic findings in different segments of the intestine.
  • Corticosteroid-free Remission: Achieving disease remission without the use of corticosteroid medications, which is a desirable outcome due to the side effects associated with long-term steroid use.
  • Anti-drug Antibodies (ADA): Antibodies produced by the body's immune system against a therapeutic drug, which can potentially reduce the drug's effectiveness or cause side effects.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-tev-48574-for-adults-with-moderate-to-severe-ulcerative-colitis-or-crohns-disease/
  2. http://clinicaltrials.eu/trial/study-on-the-long-term-effects-of-tev-48574-duvakitug-for-adults-with-moderate-to-severe-ulcerative-colitis-or-crohns-disease/